EP2038251A1 - Promédicaments hydrosolubles à charge positive de l'aspirine - Google Patents

Promédicaments hydrosolubles à charge positive de l'aspirine

Info

Publication number
EP2038251A1
EP2038251A1 EP06780025A EP06780025A EP2038251A1 EP 2038251 A1 EP2038251 A1 EP 2038251A1 EP 06780025 A EP06780025 A EP 06780025A EP 06780025 A EP06780025 A EP 06780025A EP 2038251 A1 EP2038251 A1 EP 2038251A1
Authority
EP
European Patent Office
Prior art keywords
aspirin
general formula
pro
compounds
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP06780025A
Other languages
German (de)
English (en)
Other versions
EP2038251A4 (fr
Inventor
Chongxi Yu
Lina Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YU, CHONGXI
Techfields Biochem Co Ltd
Original Assignee
Techfields Biochem Co Ltd
Chongxi Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38922980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2038251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Techfields Biochem Co Ltd, Chongxi Yu filed Critical Techfields Biochem Co Ltd
Priority to EP13155198.8A priority Critical patent/EP2610242A1/fr
Publication of EP2038251A1 publication Critical patent/EP2038251A1/fr
Publication of EP2038251A4 publication Critical patent/EP2038251A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups

Definitions

  • the present invention relates to the preparations of positively charged and water- soluble pro-drugs of aspirin or its analogues and their medicinal use in treating any aspirin-treatable conditions in humans or animals. Particularly, the present invention is to overcome the side effects that are associated with the use of salicylates. These prodrugs can be administered orally or transdermally.
  • Acetylsalicylic acid (aspirin) was synthesized in 1853 and first used medicinally in
  • Aspirin possesses antipyretic, analgesic, and anti-inflammatory properties. Because salicylates promote the excretion of uric acid, they are useful in the treatment of gouty arthritis. Aspirin also inhibits the platelet aggregation that potentially contributes to heart attacks and stroke [C. H. Hennekens, et al., N. Engl. J. Med., 321, 129(1989); T.A.Gossel, U.S. Pharmacist, February, 1988, p. 34.] and it may be protective against colon cancer as also [MJ.Thun, et al., N.
  • the salts may be acidified to acetylsalicylic acid.
  • Esters of alkyl- or aralkyl-substituted acetylsalicylic acid such as methyl-, ethyl, allyl-, or benzyl acetyl- salicylate were synthesized and studied (Boghosian, et al., U.S. Pat. No. 4,244,948). Higher fatty acid derivatives of salicylic acid and salts thereof were synthesized for use in treating aspirin-treatable conditions (Guttag, U.S. Pat. No. 5,760,261). Esters of sal sal ate with guaiacol were synthesized and evaluated pharmacologically (Nicolini, U.S. Pat. No. 4,743,704).
  • Aspirin is a very old salicylate drug (more than 100 years old) and has demonstrated anti-inflammatory, analgesic, antipyretic, and antirheumatic activities, it is also used to inhibit platelet aggregation, thus reducing cardiac mortality, and the therapeutic utility of aspirin continues to increase.
  • PDR Generics PDR Generics, 1996, second edition, Medical Economics, Montvale, New Jersey, pg 243 has listed many medical uses of aspirin.
  • GI disturbances such as dyspepsia, heartburn, vomiting, gastroduodenal bleeding, gastric ulcerations, and gastritis .
  • Gastroduodenal bleeding induced by salicylates is generally painless but can lead to fecal blood loss and may cause a persistent iron deficiency anemia.
  • uncoated aspirin at a dosage of 325 mg tablets given three times a day caused an average fecal blood loss of 4.33 ml per day (PDR Generics, 1996, second edition, Medical Economics, Montvale, New Jersey, pg 242).
  • Coated aspirin at the same dosage caused an average fecal blood loss of 1.5 ml per day.
  • Aspirin and its esters have a very low solubility in water and may stay in the GI tract for a long time and can cause gastric mucosal cell damage.
  • Aspirin and its esters are also very hydrophobic, and when they enter the cell membrane (hydrophobic layer), they will stay there as part of the membrane due to their similarity. Due to these reasons, the absorption rate of aspirin is very slow. It takes 2 hours for uncoated aspirin tablets to reach the peak salicylate level and much longer for coated aspirin tablets.
  • This invention relates to the preparation of novel positively charged pro-drugs of acetylsalicylic acid or its analogues and their use medicinally. These pro-drugs have the general formula(l) "Structure 1".
  • the goal of this invention is to avoid the side effects of aspirin by increasing the solubility of acetylsalicylic acid in gastric juice and the penetration rate of aspirin through the membrane and skin barrier which will make it administrable transdermally (topical application).
  • These novel pro-drugs of acetylsalicylic acid have two structural features in common: they have a lipophilic portion and a primary, secondary, or tertiary amine group that exists in the protonated form (hydrophilic part) at physiologic pH. Such a hydrophilic-lipophilic balance is required for efficient passage through the membrane barrier [Susan Milosovich, et al., J. Pharm. ScL, 82, 227(1993)].
  • the positively charged amino groups largely increase the solubility of the drugs.
  • the solubilities of diethylaminoethyl acetylsalicylate.AcOH and acetylsalicylic acid in pH 7 phosphate buffer were >300 mg and 0.01 mg/ml.
  • the slowest or rate-limiting step in the sequence is the dissolution of the drug.
  • Aspirin has a very low solubility in gastric juice. It stays in the GI tract for a long time and may cause gastric mucosal cell damage. When these new pro-drugs are administered orally in a dosage form such as a tablet, capsule, solution, or suspension, they will dissolve in the gastric juice immediately.
  • the positive charge on the amino groups of these pro-drugs will bond to the negative charge on the phosphate head group of membrane.
  • the local concentration of the outside of the membrane will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration.
  • the hydrophilic part will push the pro-drug into the cytosol, a semi-liquid concentrated aqueous solution or suspension. Due to the short stay in GI tract , the pro-drugs will not cause gastric mucosal cell damage.
  • Plasma levels of salicylic acid (acetylsalicyclic acid has a very short half-live, -15 minutes in plasma, so the amount of it is difficult to be determined) were determined by a specific high-performance liquid chromatography method.
  • the results ( Figure 2) show that the peak levels of salicylic acid were reached -20 minutes after application of the donor systems. It takes 2 hours for uncoated aspirin tablets to reach the peak salicylate level and much longer for coated aspirin tablets when they are taken orally. The peaks were ⁇ 0.01mg/ml for salicylic acid and -10 mg/ml for diethylaminoethyl acetylsalicylate.AcOH (approximately 100 times difference).
  • ⁇ 10mg/ml of salicylic acid in plasma is more than 33-67 times higher than the salicylate plasma level (0.15-0.3 mg/ml) for effective analgesia and 33-50 times higher than the salicylate plasma level (0.2-0.3 mg/ml) for effective anti-inflammatory activity.
  • This is a very exciting result. It will be very easy and fast to deliver therapeutically effective plasma levels of aspirin into the host by these pro-drugs.
  • the pro-drugs can be administered not only orally, but also transdermally for any kind of medical treatments.
  • the in vivo rates of penetration of other prodrugs of the general "Structure 1" are close to that of diethylaminoethyl acetylsalicylate.AcOH .
  • the acute toxicity of the pro-drugs were investigated.
  • the LD 50 orally in rats are:
  • Acetylsalicylic acid has demonstrated anti-inflammatory, analgesic, antipyretic, and antirheumatic activity, inhibits platelet aggregation, reduces cardiac mortality , but salicylic acid has only analgesic and antipyretic activity.
  • Diethylaminoethyl acetylsalicylate.AcOH has two ester function groups. One (acetyl) is from acetylsalicylic acid itself, and the one is the diethylaminoethyl ester (the added one). Both ester groups can be rapidly cleaved by the enzymes in human plasma in vitro. If the acetate group losses faster than diethylaminoethyl, the pro-durg will be changed to diethylaminoethyl salicylate, then to salicylic acid instead of acetylsalicylic acid.
  • Diethylaminoethyl acetylsalicylate.AcOH and Acetylsalicylic acid have very short half-lives ( ⁇ 4 min. and 15 min.) in whole human blood.
  • To determine how much the pro-drugs of acetylsalicylic acid were changed back to the drug itself or diethylaminoethyl salicylate we diluted whole human blood 20 times with a pH 7.4 phosphate buffer (0.2M). The cumulative amounts of diethylaminoethyl salicylate, acetylsalicylic acid, and salicylic acid were determined by a specific high-performance liquid chromatography method.
  • the rate of diethylaminoethyl salicylate vs acetylsalicylic acid is 1 vs 4. This means that 80% of the pro-drug was changed back to the drug itself. Due to the pro-drug having a much better absorption rate, the pro-drug will have more strength than the acetylsalicylic acid itself at the same dosage.
  • Analgetic activity The prolongation time of pain the threshold of a mouse tail was determined in accordance with the D'Amour-Smith Method (J. Pharmacol. Exp. Ther., 72, 74(1941)). After 200mg/kg of aspirin was administered orally and 200mg/kg of diethylaminoethyl salicylate.AcOH was administered orally and transdermally, the tails of mice were exposed to heat and the prolongation time of pain threshold was determined. The results obtained are shown in Figure 3.
  • mice were divided into 7 groups (6 mice each).
  • Aspirin ASA, 50 mg/kg and 100 g
  • AcOH Diethylaminoethyl acetylsalicylate.
  • AcOH (DEAE-ASA, 50 mg and 100 mg/kg) was administered transdermally to groups D land D2.
  • the A group is the control group.
  • the test compounds were administered to the mice 30 minutes before the acetic acid solution was administered. The results are shown in following Table 1.
  • Antipyretic activity Rats received a sterilized E. coli suspension as a pyrogen. 56 rats were divided into 7 groups. The control group is group A. 2 hours later, Aspirin (ASA, Bl for lOOmg/kg and B2 for 150mg/kg) and diethylaminoethyl acetylsalicylate.AcOH (DEAE-ASA, Cl for 100mg/kg and C2 for 150 mg) were administered orally and diethylaminoethyl acetylsalicylate.AcOH (DEAE-ASA, Dl for 100 mg and D2 for 150 mg/kg) were administered transdermally. The body temperature of rats was taken at 90 min. intervals before and after the administration of the test compounds. The results are shown in the following Table 2.
  • Anti-inflammatory activity 50 mg/kg of diethylaminoethyl acetylsalicylate.AcOH was administered orally or transdermally to rats and 50 mg/kg of aspirin was administered orally. 60 minutes later, a carrageenin solution was administered subcu- taneously to the foot pads of the rats. The volume of the hind paw was measured at every hour after the administration of the carrageenin, and the rate of increase in the volume of the paw was calculated and designated as the rate of swelling(%). The results obtained are shown in Figure 4.
  • the compounds of the general formula(l) "Structure 1" indicated above can be prepared from ASA or its analogues, or from functional derivatives of ASA or its analogues.
  • R represents CH , C H , C H , or other lower alkyl groups
  • Y represents halogen, alkoxycarbonyl or substituted aryloxycarbonyloxy, by reaction with compounds of the general formula (3) "Structure 3".
  • R represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues
  • R represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues
  • X represents O, S or NH
  • n 0,l,2,3,4,5
  • ASA or its analogues by reaction with compounds of the general formula (3) "Structure 3" by using coupling reagents, such as N,N'-Dicyclohexylcarbodiimide , N,N'-Diisopropylcarbodiimide, O-(Benzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O-(Benzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluoro phosphate, Benzotriazol- 1 -yl-oxy-tris(dimethylamino)phosphonium hexafluo- rophosphate, et al.
  • coupling reagents such as N,N'-Dicyclohexylcarbodiimide , N,N'-Diisopropylcarbodiimide, O
  • R represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues
  • R represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues
  • R 4 represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues
  • Z represents halogen, or p-toluenesulphonyl
  • a " represents Cl “ , Br “ , F, I " , AcO , acetyl- salicylate, citrate, salicylate, or any negative ions
  • n 0,l,2,3,4,5
  • R represents cross-linked resin
  • R represents CH , C H , C H , or other lower alkyl group
  • B represents any base groups, such as pyridine, piperidine, tri- ethylamine, or other base groups, by reaction with compounds of the general formula(4) "Structure 4" .
  • the present invention relates to pharmaceutical preparations comprising pro-drugs of acetylsalicylic acid and its analogues of the general formula(l) "Structure 1" in addition to customary auxiliaries and excipients, e.g. in the form of tablets, capsules or solutions for administration orally and in the form of solutions, lotion, ointment, emulsion or gel for transdermal administration transdermally.
  • the new active compounds of the general "Structure 1" can be combined with vitamins such as A,B,C or E or beta-carotene, or other pharmaceuticals, such as folic acid, et. al for treating any aspirin-treatable conditions in humans or animals .
  • Structure 1 or a composition comprising at least one compound of the general formula( 1) "Structure 1", as an active ingredient, for treating any aspirin-treatable conditions in humans or animals, especially for preventing thrombosis and other cardiovascular diseases, and cancer prophylaxis can be developed.
  • These systems can be a bandage or a patch comprising one active substance-containing matrix layer and an impermeable backing layer.
  • the most preferable system is an active substance reservoir, which has a permeable bottom facing the skin. By controlling the rate of release, this system enables aspirin to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of aspirin.
  • These systems can be worn on wrist, ankle, arm, leg, or any part of body.
  • pro-drugs of aspirin have a lipophilic portion and a hydrophilic portion (the amine groups that exist in the protonated form at physiologic pH).
  • the positively charged amino groups of these pro-drugs have two major advantages. The first, it largely increases the solubility of the drugs; when these new pro-drugs are administered orally in a dosage form such as a tablet, capsule, solution, or suspension, they will dissolve in gastric juice immediately. The second, the positive charge on the amino group of these pro-drugs will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration outside of the membrane will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration.
  • pro-drugs When these pro-drugs enter the membrane, the hydrophilic part will push the pro-drugs into the cytosol, a semiliquid concentrated aqueous solution or suspension. Due to the short stay in the GI tract, the pro-drugs will not cause gastric mucosal cell damage. Experiment results show that 80% of the prodrug was changed back to the drug itself. The pro-drugs have a much better absorption rate, and thus the pro-drugs will have better strength than the acetylsalicylic acid itself at the same dosage.
  • pro-drugs can be administered not only orally, but also transdermally for any type of medical treatment and should avoid most of the side effects of aspirin, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis.
  • SA salicylic acid
  • ASA acetylsalicylic acid
  • DEAE-ASA diethylaminoethyl acetylsalicylate.AcOH
  • FIG. 4 The rate of swelling (%) after a carrageenin injection. 1 hour before the carrageenin injection, 100 mg/kg of spirin was administered orally (B), 100 mg/kg of diethylaminoethyl salicylate.AcOH (C) was administered orally and transdermally (D). A is the control line.
  • R represents CH , C H , C H , or other lower alkyl groups
  • R represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues;
  • R represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues;
  • R 4 represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues;
  • X represents
  • the pro-drugs of of the general "Structure 1" are superior to aspirin. They may be used medicinally in treating any aspirin-treatable conditions in humans or animals. They may be used in the long-term palliative treatment of mild to moderate pain and inflammation of arthritis and other inflammatory conditions. They may be used alone or as an adjunct in the treatment of Kawasaki syndrome, thromboembolism after surgery, and unstable angina. They can be used to decrease stool volume and increase weight in acute childhood gastroenteritis, as an adjunct to prevent aortocoronary-artery -bypass graft occlusion, and to prevent thromboembolic complications in chronic artrial fibrillation.
  • They can be used as an adjunct in carotid endarterectomy to reduce platelet aggregation and thromboxane suppression, and they may be prescribed to reduce the development of cataracts, to prevent recurrence of stenosis after coronary angioplasty, and to improve cognitive performance and cerebral blood flow in patients with multi-infract dementia. They may be used as an adjunct to lower plasma glucose in diabetes mellitus and diabeties-induced complications, including diabetic retinopathy, necrobiotic ulcers, and diabetic proteinuria, and to decrease total and cardiovascular mortality.
  • They can be prescribed to reduce the incidence of hemodialysis shunt thrombosis, to decrease the deterioration of renal function and occurrence of end-stage renal disease in patients with type-1 membranoproliferative glomerulonephritis, and to slow the progression of peripheral occlussive arterial disease. They may be used in the prevention of colon cancer and rectal cancer, and arterial embolic complications in patients' prosthetic heart valves. They can also be prescribed to lower the incidence of pregnancy-induced hypertension and preeclamptic toxemia in high- risk women. It is also known that high dose of oral acetylsalicylic acid shows an an- tireactive activity by the inhibition of the cyclooxygenase activity (Bianco, Sebastiano, U.S.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur la conception et la synthèse de nouveaux promédicaments à charge positive de l'acide acétylsalicylique (ASA) et ses analogues de formule générale (1) 'Structure 1'. Les composés de formule générale (1) 'Structure 1' indiqués ci-dessus peuvent être préparés à partir de dérivés fonctionnels de l'acide acétylsalicylique ou ses analogues (par exemple d'hydracides ou d'anhydrides mélangés) par mise en réaction avec des alcools, des thiols ou des amines appropriés. Les groupes amino à charge positive de ces promédicaments peuvent non seulement augmenter largement la solubilité de ces médicaments, mais aussi se lier à la charge négative sur le groupe de tête phosphatique de membranes et pousser le promédicament vers le cytosol. Les résultats de l'expérience suggèrent que ce promédicament, l'acétylsalicylate de diéthylaminoéthyle AcOH, se diffuse à travers la peau humaine ~400 fois plus rapidement que l'acide acétylsalicylique lui-même et ~100 fois plus rapidement que l'acétylsalicylate d'éthyle. Dans le plasma, 80 % de ces promédicaments peuvent redonner le médicament en quelques minutes. Les promédicaments peuvent être utilisés médicalement dans le traitement de n'importe quel trouble pouvant être traité à l'aspirine chez l'homme ou chez l'animal et peuvent être administrés non seulement par voie orale, mais aussi par voie transdermique pour tout type de traitements médicaux. Ces promédicaments évitent également la plupart des effets secondaires de l'aspirine, plus particulièrement les troubles gastro-intestinaux tels que la dyspepsie, le saignement gastroduodénal, les ulcérations gastriques et la gastrite. Des systèmes d'administration par voie transdermique contrôlée dudit promédicament permettent à l'aspirine d'atteindre en permanence des concentrations sanguines thérapeutiques optimales pour une plus grande efficacité de l'aspirine et moins d'effets secondaires.
EP06780025A 2006-07-09 2006-07-09 Promédicaments hydrosolubles à charge positive de l'aspirine Pending EP2038251A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13155198.8A EP2610242A1 (fr) 2006-07-09 2006-07-09 Promédicaments hydrosolubles positivement chargés d'aspirine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/052318 WO2008007171A1 (fr) 2006-07-09 2006-07-09 Promédicaments hydrosolubles à charge positive de l'aspirine

Publications (2)

Publication Number Publication Date
EP2038251A1 true EP2038251A1 (fr) 2009-03-25
EP2038251A4 EP2038251A4 (fr) 2010-04-21

Family

ID=38922980

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13155198.8A Withdrawn EP2610242A1 (fr) 2006-07-09 2006-07-09 Promédicaments hydrosolubles positivement chargés d'aspirine
EP06780025A Pending EP2038251A4 (fr) 2006-07-09 2006-07-09 Promédicaments hydrosolubles à charge positive de l'aspirine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13155198.8A Withdrawn EP2610242A1 (fr) 2006-07-09 2006-07-09 Promédicaments hydrosolubles positivement chargés d'aspirine

Country Status (6)

Country Link
EP (2) EP2610242A1 (fr)
JP (1) JP5759672B2 (fr)
CN (1) CN101484415B (fr)
AU (1) AU2006346195B2 (fr)
CA (1) CA2656858C (fr)
WO (1) WO2008007171A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
WO2008010025A1 (fr) * 2006-07-18 2008-01-24 Techfields Biochem Co. Ltd Pro-médicaments d'ibuprofène hydrosolubles positivement chargés à taux de pénétration cutanée très rapide
PL2084124T3 (pl) 2006-10-02 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
CN101547898B (zh) 2006-12-10 2014-09-24 于崇曦 β-内酰胺类抗生素的透皮给药系统
HUE031712T2 (en) 2007-01-15 2017-08-28 Chongxi Yu Retinoids and retinoid-like compounds with positively charged water-soluble prodrugs having very high skin penetration rates
WO2008093173A1 (fr) 2007-01-31 2008-08-07 Chongxi Yu Promédicaments hydrosolubles à charge positive de 1h-imidazo[4, 5-c]quinolin-4-amines et composés associés à taux élevés de pénétration cutanée
KR20150058566A (ko) * 2007-06-04 2015-05-28 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 ｎｓａｉａ 약물전구체 및 이들의 새로운 의약적 용도
US20100024286A1 (en) * 2008-07-31 2010-02-04 Smith Susan Jane Liquid fuel compositions
BR122021011394B1 (pt) * 2008-12-04 2021-09-28 Chongxi Yu Composição de alta penetração de um fármaco principal, e uso de uma hpc
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
PL2427475T3 (pl) 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
US9969751B2 (en) 2009-06-10 2018-05-15 Techfields Pharma Co., Ltd. High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
WO2012137225A1 (fr) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Réactifs de méthylformyle substitué et procédé d'utilisation de ceux-ci pour modifier des propriétés physicochimiques et/ou pharmacocinétiques de composés
CN111012914A (zh) 2012-01-18 2020-04-17 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
CN112521305B (zh) * 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物
JP5905411B2 (ja) * 2013-06-12 2016-04-20 テックフィールズ バイオケム カンパニー リミテッド アスピリンの正荷電水溶性プロドラッグ
CN104276962B (zh) * 2013-07-08 2019-04-12 浙江越甲药业有限公司 一种阿司匹林衍生物及其组合物与应用
US20150072005A1 (en) * 2013-09-10 2015-03-12 Vitalis Llc Aspirin formulation for increased efficacy
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
JP6153264B2 (ja) * 2015-01-05 2017-06-28 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
CN106146326B (zh) * 2015-04-01 2022-10-11 浙江越甲药业有限公司 一种乙酰水杨酸衍生物晶体及其制备方法和用途
JP6289438B2 (ja) * 2015-12-03 2018-03-07 テックフィールズ バイオケム カンパニー リミテッド アスピリンの正荷電水溶性プロドラッグ
JP6588485B2 (ja) * 2017-02-21 2019-10-09 テックフィールズ バイオケム カンパニー リミテッド アスピリンの正荷電水溶性プロドラッグ
WO2019080693A1 (fr) 2017-10-26 2019-05-02 浙江越甲药业有限公司 Composition pharmaceutique stable contenant un dérivé de médicament anti-inflammatoire non stéroïdien
CN111556748B (zh) * 2017-11-17 2023-04-14 浙江越甲药业有限公司 一种局部麻醉药物
CN112020354A (zh) 2018-04-26 2020-12-01 Adt制药有限责任公司 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途
CN113677660A (zh) * 2018-12-29 2021-11-19 张婧 乙酰水杨酸衍生物及其应用
CN111925362B (zh) * 2020-08-20 2023-06-23 陕西中医药大学 一种抗癌化合物及其合成方法和应用
CN113599375B (zh) * 2021-06-21 2023-08-18 李萍 一种治疗口腔疾病的经口给药药物及用途
JP2025504448A (ja) * 2022-01-17 2025-02-12 テックフィールズ インコーポレイテッド 高透過プロドラッグによるウイルス感染症、細菌感染症、原生動物感染症、及び／又は真菌感染症の徴候、症状、及び／又は合併症の治療
AU2023206720A1 (en) * 2022-01-17 2024-08-29 Techfields Inc. Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
CN116082439B (zh) * 2023-03-13 2025-08-15 湖北南博生物工程有限公司 一种可用于治疗冠心病的阿司匹林衍生物及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH399486A (fr) * 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
US3966923A (en) * 1972-06-05 1976-06-29 Pierre Fabre S.A. Medicaments intended for the prevention and treatment of ischemic disturbances
US4006181A (en) * 1972-07-27 1977-02-01 Pierre Fabre S.A. Process for the obtaining of esters of acetylsalicylic acid and amino alcohols
US4012508A (en) 1975-02-03 1977-03-15 Burton Verna M Topical composition and method
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents
US4244948A (en) 1979-05-07 1981-01-13 Allergan Pharmaceuticals, Inc. Medical use of esters of acetylsalicylic acid to treat acne
US4640689A (en) 1983-08-18 1987-02-03 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
EP0152379A3 (fr) * 1984-02-15 1986-10-29 Ciba-Geigy Ag Procédé pour la préparation de compositions pharmaceutiques contenant des liposomes unilamellaires
IT1213579B (it) 1986-07-03 1989-12-20 Angelo Signor Marino Nicolini Flogistica. esteri di salsalato con guaiacolo atti al trattamento di broncopneumapatie a base
GB8813945D0 (en) * 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
HRP921157A2 (en) 1991-12-20 1994-10-31 Lohmann Therapie Syst Lts Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy
DE4341628C2 (de) * 1993-12-07 1996-05-30 Rehau Ag & Co Verfahren zur Herstellung von medizinischen Arbeitsmitteln
WO1995034813A1 (fr) * 1994-06-14 1995-12-21 Smithkline Beecham Corporation Resines pour synthese a l'etat solide
US5570559A (en) 1995-09-26 1996-11-05 Lewis; Thomas D. Fall arrestor
JPH1180107A (ja) * 1997-09-01 1999-03-26 Japan Tobacco Inc 骨形成促進剤及びアミド化合物
US6368618B1 (en) * 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
DE10034802A1 (de) 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
DE10335726A1 (de) * 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Verwendung von Hydroxyaromaten als Safener

Also Published As

Publication number Publication date
EP2610242A1 (fr) 2013-07-03
JP5759672B2 (ja) 2015-08-05
CA2656858C (fr) 2016-01-19
JP2009542797A (ja) 2009-12-03
AU2006346195B2 (en) 2013-03-07
CN101484415B (zh) 2013-08-14
CA2656858A1 (fr) 2008-01-17
CN101484415A (zh) 2009-07-15
AU2006346195A1 (en) 2008-01-17
EP2038251A4 (fr) 2010-04-21
WO2008007171A1 (fr) 2008-01-17

Similar Documents

Publication Publication Date Title
CA2656858C (fr) Promedicaments hydrosolubles a charge positive de l'acide acetylsalicylique
CA2658712C (fr) Promedicaments hydrosolubles a charge positive du diclofenac presentant une vitesse de penetration cutanee tres rapide
CA2657636C (fr) Promedicaments d'ibuprofene hydrosolubles charges positivement ayant un taux de penetration cutanee tres rapide
EP2084132B1 (fr) Promédicaments hydrosolubles positivement chargés d'acides n-arylanthraniliques à vitesse de pénétration cutanée très élevée
WO2008012603A1 (fr) Promédicaments hydrosolubles à charge positive du diflunisal et composés associés présentant une vitesse de pénétration cutanée très rapide
AU2018217329A1 (en) Positively charged water-soluble prodrugs of aspirin
AU2013206215B2 (en) Positively charged water-soluble prodrugs of aspirin
JP5905411B2 (ja) アスピリンの正荷電水溶性プロドラッグ
JP6588485B2 (ja) アスピリンの正荷電水溶性プロドラッグ
JP6289438B2 (ja) アスピリンの正荷電水溶性プロドラッグ
AU2013231152A1 (en) Positively charged water-soluble pro-drugs of ibuprofen
HK1187037A (en) Positively charged water-soluble prodrugs of aspirin
JP2018058899A (ja) アスピリンの正荷電水溶性プロドラッグ
HK1199724A1 (zh) 带有正电荷的水溶性阿司匹林前药
AU2018202140A1 (en) Positively charged water-soluble pro-drugs of ibuprofen
HK1237331A (en) Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
HK1237331A1 (en) Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
HK1188210A (en) Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
HK1198001A (en) Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate
HK1135957A (en) Positively charged water-soluble prodrugs of aspirin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 235/60 20060101ALI20100310BHEP

Ipc: C07C 327/30 20060101ALI20100310BHEP

Ipc: C07C 219/14 20060101AFI20100310BHEP

Ipc: A61P 29/00 20060101ALI20100310BHEP

Ipc: A61K 31/235 20060101ALI20100310BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100318

17Q First examination report despatched

Effective date: 20110209

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190228

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CHONGXI YU

Owner name: TECHFIELDS BIOCHEM CO. LTD

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YU, CHONGXI

Owner name: TECHFIELDS BIOCHEM CO. LTD

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230619